Crossmark

Delivery technologies for cancer immunotherapy

Crossref DOI link: https://doi.org/10.1038/s41573-018-0006-z

Published Online: 2019-01-08

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riley, Rachel S.

June, Carl H. https://orcid.org/0000-0003-0241-3557
Langer, Robert

Mitchell, Michael J.
License Information

Text and Data Mining valid from 2019-01-08
More Information

Article History

First Online: 8 January 2019

Competing interests

: R.L. receives royalties from patents (as part of Massachusetts Institute of Technology (MIT) disbursements) that MIT has licensed or holds equity or receives consulting fees from Pfizer, Translate Bio, Editas, SQZ Biotech, Capio Biosciences, Combined Therapeutics, Moderna Therapeutics, Rubius Therapeutics, Tarveda Therapeutics and Verseau Therapeutics. C.H.J. works under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc. C.H.J. is an inventor of intellectual property licensed by the University of Pennsylvania to Novartis. C.H.J. has sponsored research and equity from Tmunity Therapeutics. C.H.J. is a consultant for Immune Design, Viracta and Carisma.